The above results demonstrate that an EGFR inhibitor abrogated EGFR- or EGFRvIII-induced AR nuclear translocation, implying that EGFR can stimulate AR signaling in glioblastoma cells. The gene discussed is EGFR; the disease is glioblastoma.